- PharmAla Biotech Holdings Inc. (MDMA) has signed an agreement to be Revive Therapeutics’ (RVV) exclusive supplier of clinical-grade MDMA
- PharmAla stated it is the first publicly traded company to manufacture Good Manufacturing Practice (GMP) MDMA, known as the LaNeo MDMA Drug Product
- Revive Therapeutics is a life sciences company developing therapies for infectious diseases and rare disorders
- Revive Therapeutics (RVV) is up 7.69 per cent, trading at $0.14 per share as of 2:13 p.m. EST
- PharmAla Biotech Holdings Inc. (MDMA) is down 13.33 per cent, trading at $0.06 per share as of 2:12 p.m. EST
PharmAla Biotech Holdings (MDMA) has signed an agreement to be Revive Therapeutics’ (RVV) exclusive supplier of clinical-grade MDMA.
PharmAla stated it is the first publicly traded company to manufacture Good Manufacturing Practice (GMP) MDMA, known as the LaNeo MDMA Drug Product. It is the first company to offer two clinical-grade psychedelic active pharmaceutical ingredients.
Nick Kadysh, CEO of PharmAla, commented,
“We’re proud to be able to offer our engineering MDMA to Revive in their development of an MDMA microneedle patch and to ultimately supply them with LaNeo GMP MDMA as their development accelerates into human use.”
Revive Therapeutics is a life sciences company developing therapies for infectious diseases and rare disorders. It is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as the Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease programs.
Michael Frank, CEO of Revive Therapeutics, stated,
“Securing the supply of MDMA from PharmAla allows us to confidently advance our upcoming product and clinical development plans with our MDMA microneedle patch for mental health and abuse disorders.”
Revive Therapeutics (RVV) is up 7.69 per cent, trading at $0.14 per share as of 2:13 p.m. EST.
PharmAla Biotech Holdings Inc. (MDMA) is down 13.33 per cent, trading at $0.06 per share as of 2:12 p.m. EST.
